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Safety and tolerability of sirolimus treatment in patients with
autosomal dominant polycystic kidney disease
Abstract
BACKGROUND: We initiated a randomized controlled clinical trial to assess the effect of sirolimus on
disease progression in patients affected by autosomal dominant polycystic kidney disease (ADPKD).
Here we report the preliminary safety results of the first 6 months of treatment. METHOD: A total of 25
patients were randomized to sirolimus 2 mg/day and 25 patients to no treatment except standard care.
Treatment adherence was monitored electronically. At baseline and at Month 6, laboratory parameters
were analysed and the urinary protein profile in 24-h urine collections was determined. RESULTS: Both
treatment groups were well balanced for age, sex and renal function. In 94.1 +/- 11.4% of the study
days, patients in the sirolimus group were exposed to the drug when assuming a therapeutic efficacy
duration of 30 h. At Month 6, the mean sirolimus dose and trough level were 1.28 +/- 0.71 mg/day and
3.8 +/- 1.9 microg/l, respectively. Glomerular (albumin, transferrin, IgG) and tubular (retinol-binding
protein, alpha(1)-microglobulin) protein excretion remained unchanged. Glomerular filtration rate also
did not change significantly. Haematological parameters were similar in both groups, except for a mild
reduction of the mean corpuscular volume of erythrocytes in patients receiving sirolimus. Lipid levels
were similar in both groups. Adverse events were transient and mild, and no grade 3 or 4 events
occurred. The incidence of infections was similar in the sirolimus group (80%) and the standard group
(88%). The most common gastrointestinal adverse events were mucositis (72% in the sirolimus group
versus 16% in the standard group, P = 0.0001) and diarrhoea (36% in the sirolimus versus 20% in the
standard group, P = 0.345). CONCLUSION: Treatment of ADPKD patients with sirolimus with a dose
of 1-2 mg/day is safe and does not cause proteinuria or impairment of GFR. Treatment adherence was
excellent. (ClinicalTrials.gov number, NCT00346918.).
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Abstract 
Background 
We initiated a randomized controlled clinical trial to assess the effect of sirolimus on 
disease progression in patients affected by autosomal dominant polycystic kidney 




25 patients were randomized to sirolimus 2 mg/day and 25 patients to no treatment 
except standard care. Treatment adherence was monitored electronically. At 
baseline and month 6, laboratory parameters were analyzed and the urinary protein 
profile in 24-h urine collections was determined. 
 
Results 
Both treatment groups were well balanced for age, sex and renal function. In 
94.111.4% of the study days, patients in the sirolimus group were exposed to the 
drug when assuming a therapeutic efficacy duration of 30 hours. At month 6, the 
mean sirolimus dose and trough level were 1.280.71 mg/day and 3.81.9 µg/L, 
respectively. Glomerular (albumin, transferrin, IgG) and tubular (retinol binding 
protein, α1-microglobulin) protein excretion remained unchanged. Glomerular fitration 
rate did also not change significantly. Hematological parameters were similar in both 
groups, except for a mild reduction of the mean corpuscular volume of erythrocytes in 
patients receiving sirolimus. Lipid levels were similar in both groups. Adverse events 
were transient and mild and no grade 3 or 4 events occurred. The incidence of 
infections was similar in the sirolimus group (80%) and the standard group (88%). 
The most common gastrointestinal adverse events were mucositis (72% in the 
sirolimus group vs. 16% of the standard group, P=0.0001). 
 
Conclusion 
Treatment of ADPKD patients with sirolimus with a dose of 1 to 2 mg per day is safe 
and does not cause proteinuria or impairment of GFR. Treatment adherence was 
excellent. (ClinicalTrials.gov number, NCT00346918) 
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Introduction 
Autosomal dominant polycystic kidney disease (ADPKD) represents the most 
frequent potentially lethal monogenic hereditary disease of mankind [1]. The 
estimated number of cases in Europe and in the United States amounts to 700’000 
and 300’000, respectively. The relentless development and growth of innumerable 
cysts lead to progressive destruction of the normal renal parenchyma and massive 
enlargement of the kidneys. Subsequently the glomerular filtration rate decreases in 
an accelerated mode, and end-stage renal disease with the need for dialysis and/or 
transplantation ensues. Data from the consortium for radiologic imaging studies of 
polycystic kidney disease (CRISP) have shown that the rate of kidney volume growth 
is an excellent predictor of renal functional decline [2]. Therefore kidney volume 
growth can be used as a surrogate marker of disease progression [3]. Despite 
decades of intense basic and clinical research, effective treatment which alters the 
course of ADPKD has not been established. 
 
Sirolimus, also termed rapamycin, is an immunosuppressant that binds to FK binding 
protein-12 (FKBP-12) and inhibits the activation of mTOR, a key regulatory kinase of 
growth and proliferation [4]. We and others have previously shown that the mTOR 
inhibitors sirolimus and everolimus effectively reduce cyst growth and loss of renal 
function in an experimental animal model for polycystic kidney disease (PKD) [5-7]. 
Additional studies have shown that sirolimus is also effective in various mouse 
models of PKD, including dominant and recessive forms [8]. Of interest, analyses of 
ADPKD patients that received a renal allograft revealed that cystic kidney and liver 
volumes regressed under immunosuppression with sirolimus [8,9]. 
 
Based on these encouraging studies we have initiated a randomized controlled 
clinical trial as a proof-of-concept study to examine the effect of sirolimus on cyst 
volume growth in young patients with documented ADPKD and normal GFR [10]. 
Here we report the preliminary safety and tolerability results of this clinical trial, with 
particular emphasis on the effect of sirolimus on proteinuria and GFR. 
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Methods 
Patient population and study design 
The SUISSE ADPKD study represents an ongoing single center, prospective, open-
label, randomized controlled clinical trial to assess the efficacy of sirolimus 
(Rapamune®) to decrease renal volume enlargement in patients with ADPKD. The 
study involves 100 ADPKD-patients aged 18-40 years with an estimated creatinine 
clearance >70 ml/min. Prior to randomization, polycystic kidneys are visualized by 
MRI without contrast media within an interval of 6 months and kidney and cyst 
volumes are measured by volumetry. The volumetry method has been previously 
validated and showed an excellent reliability [3]. Patients with documented total 
kidney volume enlargement of >2% are randomized at a one to one ratio to sirolimus 
2 mg per day or standard care for 18 months. At the discretion of the treating 
physician the starting dose was reduced to 1 mg in case of anticipated sirolimus-
associated toxicity. An independent biostatistics unit generated the randomisation 
list, using a permuted blocks design with a random block size of 4 or 6 to guarantee a 
balanced allocation. Patients in the standard arm had visits at month 3 and 6, and 
patients in the sirolimus arm had four extra visits at week 2 and 4 and month 1 and 2 
after randomization to allow for blood level monitoring and dose adjustments. The 
sirolimus dose was reduced or withheld when the through level exceeded 10 µg/l, or 
when elevated liver enzymes (>2-fold above normal values), thrombopenia 
(<100'000/mm3), leukopenia (<3'000/mm3) occurred. Standard care included blood 
pressure control and symptomatic treatment of flank pain, cyst bleedings and cyst 
infections. 
 
The study was approved by the institutional review board and is conducted according 
to Good Clinical Practice guidelines and the Declaration of Helsinki, and is controlled 
by external monitoring. All participants gave written informed consent. Details of the 
study design have been reported elsewhere [10]. Briefly, from a local prospective 
ADPKD cohort we selected 100 patients with documented total kidney volume (TKV) 
progression for inclusion (i.e. randomization) in the trial. Approximately 80% of 
patients considered for randomization had ≥2% TKV progression within an interval of 
6 months (data not shown). According to a predefined interim analysis plan, the first 
50 patients that had completed 6 months of sirolimus treatment (n=25) or standard 
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care (n=25) were subjected to a safety and tolerability analysis,. The entire study is 
powered to enroll a total of 100 patients and to continue until there is a mean 18-
month follow up. Here we report on the first 50 randomized patients, focusing 
particularly on the safety and tolerability of sirolimus treatment. 
Study procedures 
A detailed medical history was obtained from all patients, including ADPKD-related 
symptoms, previous hospitalizations and medication. Blood pressures were 
measured twice 5 minutes apart in each arm in the sitting position after a rest of 5 
minutes, using an oscillometric blood pressure monitor (Boso-Medicus, Jungingen, 
Germany) at each visit. The lower of the two consecutive measurements in the arm 
with the higher blood pressure was used for analysis. Arterial hypertension was 
defined as systolic blood pressure 140 mmHg or diastolic blood pressure 90 mm 
Hg at ≥2 study visits, or treatment with an antihypertensive drug. 
 
Adherence to the prescribed study drug was assessed during the entire treatment 
period by an electronic system that monitors the date and time of the medication 
bottle opening (MEMS®, Aardex, Ltd., Zug, Switzerland). The electronic system 
reliably assesses the medication adherence as a period with a lack of medication 
bottle opening, which was considered to represent an episode of non-adherence 
[11,12]. The percent of time where the patient was exposed to the drug action was 
calculated based on two different estimates of duration of therapeutic efficacy of 
sirolimus, namely 24 hours plus 6 hours (6 hours forgiveness period) and 24 hours 
plus 24 hours (24 hours forgiveness period).  
Laboratory analyses 
Blood was obtained for the determination of creatinine (IDMS traceable modified 
Jaffé method), lipids, liver enzymes and hematologic parameters including 
erythrocyte indices. Trough levels of sirolimus were determined by liquid 
chromatography–mass spectrometry in samples of whole blood.  
 
24-h urine samples were collected at baseline and at month 6. Aliquots of these urine 
samples were centrifuged at 1500 g for 5 min, and the supernatants were stored at -
80°C prior to analysis. Albumin, transferrin and immunoglobulin G (IgG) were 
analyzed as urinary markers of glomerular damage, and retinol binding protein (RBP) 
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and 1-microglobulin as urinary markers of tubular damage. Measurement of urinary 
total protein (benzethonium chloride method, Roche Ltd., Basel, Switzerland) and 
serum creatinine (enzymatic method, Wako Pure Chemical Industries Ltd., Osaka, 
Japan) were performed on a Hitachi 917 analyzer, while urinary marker proteins were 
measured on a Beckman-Coulter nephelometry system (Beckman-Coulter, Brea, 
USA) using antibodies against albumin, transferrin, IgG and 1-microglobulin, 
(Beckman-Coulter, Brea, USA) and RBP (Dako, Glostrup, Danmark). The inter-assay 
coefficient of variation was <5% for these assays. The lower limit of quantification of 
the assays were 0.04 g/l for total protein, 2.0 mg/l for albumin, 0.61 mg/l for 
transferrin, 3.0 mg/l for IgG, 0.328 mg/l for RBP and 4.0 mg/l for 1-microglobulin [13] 
Concentration values in urine samples below the lower limit of quantification were set 
to zero for all calculations. 
Safety Assessment 
Safety was determined on the basis of the occurrence of adverse events, findings on 
physical examination, and laboratory evaluations. Adverse events affecting ≥5% in 
either group were described and graded according to the National Cancer Institute 
(NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 [14]. A 
patient with multiple occurrences of an adverse event was counted once in the 
corresponding category and a patient with multiple adverse events within a primary 
system organ class was also counted once for that class. Primary system organ 
classes and preferred terms were sorted by the frequency of adverse events in the 
total group. Safety and tolerability analyses included all randomized patients who 
received at least one dose of sirolimus and underwent at least one safety 
assessment.  
Statistics 
Results are expressed as means  standard deviation or number of patients 
(percent). For comparisons between groups, means of continuous data were 
compared by Student’s t test or by the Wilcoxon rank-sum test as appropriate and 
categorical data by Fisher's exact test. All P values were two sided for the 
comparison between the groups or between baseline and follow-up values, and 
those less than 0.05 were considered statistically significant.  
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Results 
Characteristics of the patients 
Here we report on 50 ADPKD patients that were enrolled from March 2006 to March 
2007 and that have completed the first 6 months of the treatment. 25 patients were 
randomly assigned to receive sirolimus and 25 patients to receive no treatment 
except standard care. Table 1 shows that both treatment groups were well balanced 
at baseline for age, sex, body mass index (BMI) and blood pressure. Approximately 
70% of patients in each group had hypertension, mostly treated with angiotensin-
converting enzyme inhibitors or angiotensin receptor blockers. None of the patients 
were lost to follow up. 
Study drug adherence 
In 94.1  11.4% of the study days, patients in the sirolimus group were exposed to 
the drug if the duration of therapeutic efficacy was assumed to be 30 hours or in 96.6 
 9.7% of the days supposing a therapeutic drug action of 48 hours. The percentage 
of days with correct dosing was 93.0  12.1%. 17 patients received the correct 
sirolimus dose in >95% of the study days assuming 30 hours of sirolimus therapeutic 
duration. The number of patients with correct dosing at >95% of the study days 
amounted to 22 patients if the therapeutic efficacy duration of sirolimus was set to 48 
hours.  
Sirolimus dose and whole blood trough levels 
Figure 1 shows the sirolimus dose and sirolimus whole blood trough levels. The 
starting dose was reduced to 1 mg per day in 9 patients, mostly females (8 females, 
1 male), due to anticipated more severe side effects in young female ADPKD 
patients. After adjustment of the sirolimus dose in the first two months, the sirolimus 
dose, dose per body weight and whole blood trough levels remained constant and at 
6 months amounted to 1.28  0.71 mg/day, 0.018  0.01 mg/day/kg and 3.8  1.9 
µg/L, respectively.  
Effect of sirolimus on renal function and urinary protein excretion 
Renal function assessed by measured and estimated creatinine clearance as well as 
serum creatinine was similar in the sirolimus group and standard group at baseline 
and month 6 (Table 2). Thus, sirolimus did not adversely affect GFR. 
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Since it is well known that sirolimus can cause proteinuria in patients with preexisting 
renal disease we examined in detail the urinary protein profile in 24h-urine collections 
(Table 2). The median urinary excretion of total protein was low, and similar in both 
groups at baseline (78.0 mg/day in the sirolimus group vs. 65.0 mg/day in the 
standard group, P=0.077) and at month 6 (120 mg/day in the sirolimus group vs. 86.3 
mg/day in the standard group, P=0.087). The median urinary excretion of albumin 
was low in both groups at baseline (13.7 mg/day in the sirolimus group vs. 9.0 
mg/day in the standard group, P=0.450) and remained low in response to sirolimus 
treatment (36.0 mg/day in the sirolimus group vs. 18.9 mg/day in the standard group 
at 6 months, P=0.349, Figure 2). The number of patients developing 
microalbuminuria (as defined by urinary albumin excretion >30 mg/24h) during the 6 
month interval was similar in each group (+3 patients in the sirolimus group vs. +2 
patients in the standard group) and none of the patients had macroalbuminuria 
(defined by urinary albumin excretion >300 mg/24h) at any time point. Furthermore, 
the urinary excretion of transferrin did not change significantly during the 6-month 
interval. The changes in the urinary protein excretion that occurred within the 6-
month interval were similar in each group (sirolimus vs. standard mean changes of 
albumin +8.4 mg/24h, P=0.543, transferrin +0.18 mg/mmol, P=0.791 and total protein 
-1.8 mg/24h, P=0.938). IgG was detectable in 4 and 2 urine samples of the control 
group and in 2 and 7 urine samples of the sirolimus group at baseline and at 6 
months, respectively. 
 
Regarding the tubular proteins, RBP was only detectable at low concentration in one 
urine sample at month 6 and was below the lower limit of quantification in all other 
samples. Likewise 1-microglobulin was only detectable in 3 and 6 urine samples of 
the standard group and in 2 and 4 urine samples of the sirolimus group at baseline 
and at 6 months, respectively. In urine samples of 10 patients of the standard group 
and of 9 patients of the sirolimus group, RBP or IgG or 1-microglobulin was 
detectable at any time point of the study.  
 
Taken together, the urinary excretion of markers for glomerular and tubular damage 
remained unchanged during the 6 month interval and was not adversely affected by 
sirolimus treatment. 
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Effect of sirolimus on clinical and laboratory parameters 
Table 3 shows, that the BMI and blood pressure were similar in the sirolimus and in 
the standard group month 6. We also analyzed the influence of sirolimus on the 
antihypertensive treatment. At baseline 40% patients in the sirolimus group and 48% 
patients in the standard group received an anti-hypertensive medication, mostly 
angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor antagonists 
(ARB). The number of patients that started a new ACEi or ARB treatment during the 
6-month treatment phase (30% of the sirolimus group vs. 10% of the standard group) 
was also similar.  
 
Sirolimus can cause hematological alterations in renal transplant recipients. The 
mean hemoglobin, mean corpuscular hemoglobin concentration (MCHC), leukocyte 
and platelets counts did not differ significantly in the two groups of ADPKD patients 
(Table 2). The red blood cell count was unchanged; whereas, the mean corpuscular 
volume (MCV) and the mean corpuscular hemoglobin (MCH) were significantly lower 
in patients receiving sirolimus compared to patients in the standard group (Figure 3). 
Also the percentage of microcytic erythrocytes was higher in patients on sirolimus 
(1.3 ± 2.3% in the standard group vs. 2.2 ± 1.3% in the sirolimus group, P=0.002). 
 
The mean aspartate aminotransferase (AST) value was significantly higher in 
patients receiving sirolimus at 6 months. However all values of individual patients 
remained below the limit of 2-fold upper limit of normal range in either group. The 
mean alanine aminotransferase and gamma-glutamyltransferase values were similar 
in both groups.  
 
Sirolimus is known to cause hyperlipidemia. The mean cholesterol, low-density 
lipoprotein (LDL), high-density lipoprotein (HDL) and triglyceride levels did not differ 
significantly among the groups (Figure 4). The ratio of LDL to HDL cholesterol was 
also similar among the groups. Although sirolimus treatment was associated with a 
tendency to higher values of triglyceride and cholesterol, the range of values and 
numbers of patients above the pre-defined cut-offs were similar in both groups at 
month 6. One patient started a statin treatment in the sirolimus group and none of the 
patients in the standard group. 
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Adverse events 
Table 4 lists the adverse events. All patients reported at least one adverse event 
during the 6 months in both groups. No grade 3 or 4 events were reported. The 
incidence of any infection was similar in the sirolimus group (80%) and the standard 
group (88%). The most frequent infection was upper respiratory infection and its 
incidence was also similar in the sirolimus group (64%) and in the standard group 
(80%). No clinically significant opportunistic infections were reported. Headache was 
more common among patients receiving sirolimus (48%) than among patients of the 
standard group (12%). The total number of patients with gastrointestinal adverse 
events was higher in the sirolimus group (84%) than in the standard group (32%). 
The most common gastrointestinal adverse events were mucositis (72% of the 
sirolimus group vs. 16% of the standard group, P=0.0001) and diarrhea (36% of the 
sirolimus group vs. 20% of the standard group, P=0.345). A total of 48% patients in 
the sirolimus group had adverse events leading to sirolimus dose reduction, namely 
mucositis (16%), tooth extraction (8%), acne (4%), sirolimus trough level >10 g/L 
(4%), infection (4%), leucopenia (4%) and surgery (4%).  
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Discussion 
Sirolimus is an immunosuppressant drug with strong anti-proliferative properties. It 
has been approved for the prevention of rejection after kidney and liver 
transplantation and is used in combination with other immunosuppressive drugs. The 
favourable effect of sirolimus in rodent models for ADPKD has prompted the initiation 
of clinical trials testing the efficacy of sirolimus in halting polycystic kidney disease 
progression. The potential risks of a sirolimus treatment have limited its use in 
transplantation and may hamper a potential therapeutic application in ADPKD 
patients. In this trial, however, we show that sirolimus at doses of 1 to 2 mg per day 
were well tolerated and safe in ADPKD patients.  
 
There have been reports of nephrotoxicity and proteinuria related to sirolimus use in 
solid organ transplant recipients. Studies have shown an increase in urinary protein 
excretion in patients converted from calcineurin inhibitor-based therapy to sirolimus 
therapy as well as with de novo use of sirolimus [15-17]. The origin of sirolimus-
associated urinary protein excretion, i.e. glomerular vs. tubular origin is still a subject 
of investigations. However, proteinuria associated with the use of sirolimus is mainly 
composed of albumin, and angiotensin converting enzyme inhibitors effectively 
reduce the mTOR inhibitor-induced proteinuria, suggesting that sirolimus increases 
glomerular permeability [18]. In addition to albuminuria, glomerular proteinuria is 
characterized by increased excretion of transferrin and IgG, two glomerular markers 
with different molecular weights which allow to distinguish selective from unselective 
proteinuria [19]. We analyzed in detail the urinary protein excretion in 24h urine 
collections and found unchanged levels of albumin, transferrin and IgG. Furthermore, 
the urinary excretion of the low-molecular weight proteins 1-microglobulin and RBP, 
characterizing tubular proteinuria [20], was unchanged by sirolimus treatment. 
Together these data reveal that albuminuria is minimal in young patients affected by 
ADPKD. The mild albuminuria which is seen in some patients results from glomerular 
leaking. Sirolimus at a dosage between 1 and 2 mg/day did not significantly 
deteriorate glomerular proteinuria, or induce tubular proteinuria. Since a 6-month 
treatment with sirolimus did also not impair the GFR, sirolimus appears to have an 
excellent renal safety profile in ADPKD patients. 
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In two randomized, double-blind multicenter studies the safety and efficacy of 
sirolimus compared with azathioprine (Study 1) [21] or placebo (Study 2) [22] in 
combination with cyclosporine and prednisone for the prevention of rejection after 
renal transplantation were examined. These studies compared the dose of 2 mg or 5 
mg of sirolimus per day. For the dose of 2 mg per day the following side effects 
compared to the control group were seen more frequently: Hypercholesterolemia, 
hypertriglyceridemia, hypertension, thrombocytopenia, acne and skin rash. All side 
effects occurred in co-medication with cyclosporine and prednisone. We found 
unchanged lipid levels, although there is abundant evidence that sirolimus causes an 
increase in serum triglyceride levels and in the levels of cholesterol, LDL and HDL 
[23]. In our current study, sirolimus treatment was associated with tendency to higher 
values of cholesterol, low-density lipoprotein (LDL) and triglyceride. These changes 
reached not statistical significance, most probably due to type II error. Metabolic 
balance studies have also shown that the defect in lipid metabolism is largely dose-
dependent [24].  
 
Leukocyte and platelets counts remained unchanged. However, we noted a mild but 
significant reduction of erythrocyte volume in patients treated with sirolimus. Several 
studies with sirolimus in differently combined immunosuppressive regimen as well as 
one study with the sirolimus derivate everolimus as a monotherapy have reported 
reduced MCV and microcytosis in solid organ transplant recipients [25-29]. The 
aetiology of the reduced MCV is not well understood. In these previous studies, 
patients received concomitant immunosuppressive medication to prevent organ 
rejection, iron supplementation and erythropoietin stimulation agents for the 
treatment of anemia and many patients had impaired kidney function, factors that 
may influence the morphological characteristic of erythrocytes. In our current study, 
we are able to ascribe this sirolimus-associated effect on MCV and MCH to the drug 
itself. These changes occurred at a low sirolimus trough level and were not 
accompanied by a decrease of leukocyte, platelet or red blood cell count, and are 
therefore not attributable to the well-known anti-proliferative effect of sirolimus on 
bone morrow colony-forming cells. Our finding of a disproportionately low MCV in 
comparison with unchanged red blood cell count suggests a defect in the globin 
synthesis. The globin protein synthesis is under tight control of eukaryotic initiation 
factor 2 (eIF2) and the phosphorylation of eIF2α prevents translation initiation and 
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hence the synthesis of globin. As rapamycin causes an increase in phosphorylation 
of eIF2α, we speculate that the decrease in erythrocyte volume and hemoglobin 
content seen in our patient is due to reduced globin synthesis rather than an impaired 
red blood cell production. [30,31]  
 
Adverse events were transient and mild and no serious adverse events occurred in 
our study. The incidence of infections was similar in both groups whereas oral ulcers 
and headache occurred more frequently among patients receiving sirolimus 
compared to patients receiving standard care. Oral adverse events, usually involving 
superficial ulcerations of the gingival and buccal mucosa and tongue, named 
aphthous mouth ulcers, have been reported in patients receiving sirolimus. Aphthous 
mouth ulcers occurred in 10-19% of patients receiving sirolimus in phase III clinical 
trials [21,22] and in up 32% in patients switched from a calcineurin inhibitor therapy 
to sirolimus [32]. Notably, the co-medication with corticosteroids may decrease the 
risk for sirolimus associated aphthous mouth ulcers. In a cohort of patients converted 
to sirolimus in the absence of corticosteroids a high incidence (up to 60%) was 
reported for this complication [33]. We found a 72% incidence of aphthous mouth 
ulcers among ADPKD patients treated with sirolimus. Various hypotheses concerning 
the cause of these ulcers have been generated without clear evidence. The strong 
anti-proliferative properties of sirolimus might function as the primary trigger for the 
development of these ulcers and the absence of corticosteroids may hamper their 
secondary healing. Additionally, the true incidence of this adverse event might be 
underestimated as these mucosal lesions can easily be mistaken for herpes simplex 
infection [34]. The incidence of headache was higher in patients receiving sirolimus. 
Thus far headaches were not known side-effects of sirolimus treatment. Our finding 
has recently been validated by analyzing pharmacovigilance data in other patient 
populations. As a consequence, the product information is being adapted on a 
worldwide basis to include this information. 
 
A limitation of our study is the low number of patients and the short time of follow-up. 
Therefore we cannot exclude the occurrence of rare adverse events or events 
occurring only after long-term treatment. However, based on experience in other 
patient populations treated with sirolimus we anticipated that we could detect major 
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side effects/adverse events in the sirolimus-treated patients with sufficient robustness 
in a relatively homogeneous ADPKD population in a 6 month time interval. 
 
In conclusion, this short-term analysis reveals that sirolimus treatment is safe for 
ADPKD patients when the drug is used at a dosage between 1 to 2 mg per day. 
Treatment adherence was excellent, the renal safety profile was encouraging and the 
characteristic side effects of sirolimus were well manageable. The DSMB has 
therefore recommended continuation of the study. The upcoming efficacy data of this 
trial will establish whether sirolimus has a beneficial effect on the relentlessly 
progressive cyst volume growth in patients with ADPKD. 
15 von 23 
 
Acknowledgements 
Funding for this study was supported by the Swiss National Science Foundation (No 
310000-118166), by the Polycystic Kidney Foundation (Kansas, MO, USA) and by an 
unrestricted research grant of Wyeth Europe. The authors thank Michael Pickering 
(BIOP, Basel, Switzerland), Julia Hofmann, Ruth Russi and Marian Struker for the 
excellent technical assistance. We thank the following nephrologists for contributing 
patients: D. Aerne, J.A. Bleisch, A. Bock, W. Brunner, M. Cicvara, H.J. Gloor, Z. 
Glück, B.A. Gürtler, E. Grüter, H.M. Herb, D. Hertner, C. Jäger, H. Jungbluth, C. Kell, 
G. Keusch, M. Mayr, N. Höfliger, H.R. Räz, P. Ruedin, H. Saxenhofer, D. Schiesser, 
M. Schmid, C. Schönholzer, A.K. Schwarzkopf, M. Spöndlin, J. Steiger, C. Wahl. 
 
Disclosure 
The author(s) declare that they have no competing interests. 
 
16 von 23 
 
References 
1. Dalgaard OZ. Bilateral polycystic disease of the kidneys; a follow-up of two 
hundred and eighty-four patients and their families. Acta Med Scand Suppl 
1957; 328:1-255. 
2. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic 
kidney disease. N Engl J Med 2006; 354:2122-30. 
3. Kistler AD, Poster D, Krauer F, et al. Increases in kidney volume in autosomal 
dominant polycystic kidney disease can be detected within 6 months. Kidney Int 
2009; 75:235-41. 
4. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 
103:253-62. 
5. Wahl PR, Serra AL, Le Hir M, et al. Inhibition of mTOR with sirolimus slows 
disease progression in Han:SPRD rats with autosomal dominant polycystic 
kidney disease (ADPKD). Nephrol Dial Transplant 2006; 21:598-604. 
6. Wu M, Wahl PR, Le Hir M, et al. Everolimus retards cyst growth and preserves 
kidney function in a rodent model for polycystic kidney disease. Kidney Blood 
Press Res 2007; 30:253-9. 
7. Tao Y, Kim J, Schrier RW, et al. Rapamycin markedly slows disease 
progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 
2005; 16:46-51. 
8. Shillingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated 
by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic 
kidney disease. Proc Natl Acad Sci U S A 2006; 103:5466-71. 
9. Qian Q, Du H, King BF, et al. Sirolimus reduces polycystic liver volume in 
ADPKD patients. J Am Soc Nephrol 2008; 19:631-8. 
10. Serra AL, Kistler AD, Poster D, et al. Clinical proof-of-concept trial to assess the 
therapeutic effect of sirolimus in patients with autosomal dominant polycystic 
kidney disease: SUISSE ADPKD study. BMC Nephrol 2007; 8:13. 
11. Farmer KC. Methods for measuring and monitoring medication regimen 
adherence in clinical trials and clinical practice. Clin Ther 1999; 21:1074-90; 
discussion 3. 
12. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 
353:487-97. 
13. Regeniter A, Siede WH, Scholer A, et al. Interpreting complex urinary patterns 
with mdi lablink: a statistical evaluation. Clinica Chimica Acta 2000; 297:261-73. 
14. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a 
comprehensive grading system for the adverse effects of cancer treatment. 
Semin Radiat Oncol 2003; 13:176-81. 
15. Senior PA, Paty BW, Cockfield SM, et al. Proteinuria developing after clinical 
islet transplantation resolves with sirolimus withdrawal and increased tacrolimus 
dosing. Am J Transplant 2005; 5:2318-23. 
16. Butani L. Investigation of pediatric renal transplant recipients with heavy 
proteinuria after sirolimus rescue. Transplantation 2004; 78:1362-6. 
17. Saurina A, Campistol JM, Piera C, et al. Conversion from calcineurin inhibitors 
to sirolimus in chronic allograft dysfunction: changes in glomerular 
haemodynamics and proteinuria. Nephrol Dial Transplant 2006; 21:488-93. 
18. Letavernier E, Pe'raldi MN, Pariente A, et al. Proteinuria following a switch from 
calcineurin inhibitors to sirolimus. Transplantation 2005; 80:1198-203. 
17 von 23 
19. Maachi M, Fellahi S, Regeniter A, et al. Patterns of proteinuria: urinary sodium 
dodecyl sulfate electrophoresis versus immunonephelometric protein marker 
measurement followed by interpretation with the knowledge-based system MDI-
LabLink. Clin Chem 2004; 50:1834-7. 
20. D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int 2003; 63:809-
25. 
21. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of 
acute renal allograft rejection: a randomised multicentre study. The Rapamune 
US Study Group. Lancet 2000; 356:194-202. 
22. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and 
efficacy study of a sirolimus/cyclosporine regimen for prevention of acute 
rejection in recipients of primary mismatched renal allografts. Transplantation 
2001; 71:271-80. 
23. Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin 
inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 
8:1384-92. 
24. Hoogeveen RC, Ballantyne CM, Pownall HJ, et al. Effect of sirolimus on the 
metabolism of apoB100- containing lipoproteins in renal transplant patients. 
Transplantation 2001; 72:1244-50. 
25. Cahill BC, Somerville KT, Crompton JA, et al. Early experience with sirolimus in 
lung transplant recipients with chronic allograft rejection. J Heart Lung 
Transplant 2003; 22:169-76. 
26. Kim MJ, Mayr M, Pechula M, et al. Marked erythrocyte microcytosis under 
primary immunosuppression with sirolimus. Transpl Int 2006; 19:12-8. 
27. Masetti M, Rompianesi G, Montalti R, et al. Effects of everolimus monotherapy 
on hematological parameters and iron homeostasis in de novo liver transplant 
recipients: preliminary results. Transplant Proc 2008; 40:1947-9. 
28. Sanchez Fructuoso A, Calvo N, Moreno MA, et al. Study of anemia after late 
introduction of everolimus in the immunosuppressive treatment of renal 
transplant patients. Transplant Proc 2007; 39:2242-4. 
29. Maiorano A, Stallone G, Schena A, et al. Sirolimus interferes with iron 
homeostasis in renal transplant recipients. Transplantation 2006; 82:908-12. 
30. Cherkasova VA, Hinnebusch AG. Translational control by TOR and TAP42 
through dephosphorylation of eIF2alpha kinase GCN2. Genes Dev 2003; 
17:859-72. 
31. Kubota H, Obata T, Ota K, et al. Rapamycin-induced translational derepression 
of GCN4 mRNA involves a novel mechanism for activation of the eIF2 alpha 
kinase GCN2. J Biol Chem 2003; 278:20457-60. 
32. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late 
conversion from CNI-based to sirolimus-based immunosuppression following 
renal transplantation. Am J Transplant 2005; 5:2496-503. 
33. van Gelder T, ter Meulen CG, Hene R, et al. Oral ulcers in kidney transplant 
recipients treated with sirolimus and mycophenolate mofetil. Transplantation 
2003; 75:788-91. 
34. Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug 
Saf 2005; 28:153-81. 
 
 
18 von 23 








Age (years) 29 ± 6 29 ± 6 0.964 
Gender, No. of male patients (%) 14 (56) 20 (80) 0.069 
BMI (kg/m2) 24 ± 4 25 ± 4 0.284 
Systolic blood pressure (mm Hg) 131 ± 16 131 ± 15 0.985 
Diastolic blood pressure (mm Hg) 87 ± 11 83 ± 10 0.122 
Hypertension, No. (%) 17 (68) 17 (68) 1.000 
Antihypertensive treatment, No. (%)  
All 10 (40) 12 (48) 0.776 
ACEi and/or ARB therapy 8 (32) 11 (44) 0.561 
Diuretics 2 (8) 5 (20) 0.417 
Others 3 (12) 3 (12) 1.000 
Symptoms and complications of ADPKD, No. (%)  
History of flank pain 6 (24) 15 (60) 0.021 
History of macrohematuria 6 (24) 6 (24) 1.000 
History of cyst infections 1 (4) 3 (12) 0.609 
History of intracranial bleeding 0 (0) 1   (4) 1.000 
≥2 complications of ADPKD 3 (12) 4 (16) 1.000 
Family history of intracranial bleeding 3 (12) 4 (16) 1.000 
  
 
* Table shows either the mean ± standard deviation or number of patients (percent). 
BMI denotes body mass index, ACEi angiotensin-converting enzyme inhibitor, and 
ARB angiotensin receptor blocker. 
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Table 2. Changes in renal function and urinary protein excretion from baseline to month 6.* 
 
   Baseline  Month 6 











mCrCl (24-urine collection) ml/min 90-120 91.7 ± 42.7 92.7 ± 46.7 0.937  110.1 ± 31.8 110.0 ± 30.7 0.996
eCrCl (Cockcroft Gault formula) ml/min 90-120 105.1 ± 25.4 114.1 ± 23.0 0.195  109.2 ± 24.1 113.9 ± 21.7 0.474
Serum creatinine µmol/L 62-106 men 90.5 ± 18.3 95.4 ± 18.1 0.345  87.3 ± 15.7 96.2 ± 17.5 0.065
  44-80 women   
Urinary excretion (24-urine collection)     
Albumin, median (IQR) mg/24h <20 13.7 (7.4 to 25.2) 9.0 (4.0 to 27.2) 0.450  36.0 (12.0 to 65.0) 18.9 (9.2 to 46.7) 0.349
Transferrin, median (IQR) mg/24h <1.7 0.87 (0.00 to 3.00) 0.00 (0.00 to 1.84) 0.280  2.04 (1.26 to 3.86) 1.48 (0.00 to 2.63) 0.273
Total protein, median (IQR) mg/24h <100 78.0 (60.0 to 123.0) 65.0 (42.0 to 92.0) 0.077  120.0 (84.0 to 175.0) 86.8 (73.9 to 114.0) 0.087
IgG levels above LLQ, No. (%)   2 (8) 4 (16)   7 (36) 2 (8) 0.138
RBP levels above LLQ, No. (%)   0 (0) 0 (0)   0 (0) 1 (4) 1.000
A1M levels above LLQ, No. (%)   2 (8) 3 (12)   4 (16) 6 (24) 0.715
     
* Table shows either the mean  standard deviation or number of patients (percent), with the exception of urinary albumin, transferrin and 
total protein excretion values, which are given as medians with interquartile range because of skewed data distribution. mCrCl denotes 
measured creatinine clearance, eCrCl estimated creatinine clearance, CG Cockcroft Gault, IQR interquartile range, IgG immunoglobulin G, 
LLQ lower limit of quantification, RBP retinol binding protein and A1M 1-microglobulin.  
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BMI (kg/m2)  
Mean ± SD 24 ± 4 25 ± 3 0.314 
Range 18 – 30 17 – 35  
Systolic blood pressure (mm Hg)  
Mean ± SD 126 ± 15 134 ± 12 0.054 
Range 96 – 156 103 – 160  
Diastolic blood pressure (mm Hg)  
Mean ± SD 83 ± 8 85 ± 9 0.505 
Range 60 – 101 70 – 102 0.702 
Antihypertensive treatment, No. (%)  
All  15 (60) 15 (60) 1.000 
ACEi and/or ARB therapy 14 (56) 14 (56) 1.000 
Diuretics 3 (12) 5 (20)  
Others 3 (12) 3 (12) 1.000 
Hemoglobin (grams/liter)  
Mean ± SD 139.4 ± 8.49 144.2 ± 11.19 0.097 
Range 118 – 154 128 – 166  
MCV (femtoliter)  
Mean ± SD 82.40 ± 3.81 84.12 ± 4.47 0.005 
Range 77.80 – 92.50 71.00 – 94.40  
MCH (picogram/cell)  
Mean ± SD 28.88 ± 0.64 30.25 ± 1.91 0.009 
Range 26.50 – 32.60 23.60 – 32.50  
MCHC (grams/deciliter)  
Mean ± SD 35.04 ± 2.15 35.24 ± 1.34 0.465 
Range 32.10 – 36.90 33.20 – 37.20  
Leukocyte count (x10-3/mm3)  
Mean ± SD 6.03 ± 2.06 5.81 ± 1.64 0.673 
Range 3.0 – 12.2 3.9 – 12.2  
Platelet count (x10-3/mm3)  
Mean ± SD 253.7 ± 63.11 253.3 ± 53.70 0.981 
Range 146.0 – 380.0 172.0 – 386.0  
AST (U/l)  
Mean ± SD 30.28 ± 8.54 24.92 ± 4.76 0.010 
Range 19 – 53 17 – 36  
Number of patients > 2 x ULN 0 0  
ALT (U/l)  
Mean ± SD 33.96 ± 25.79 26.36 ± 14.90 0.109 
Range 9 – 114 12 – 71  
Number of patients > 2 x ULN 1 0  
Cholesterol (mmol/liter)  
Mean ± SD 4.94 ± 1.19 4.52 ± 0.84 0.147 
Range 3.4 – 8.5 3.1 – 7.1  
Number of patients  ≥6.2 4 1  
LDL cholesterol (mmol/liter)  
Mean ± SD 2.89 ± 1.01 2.66 ± 0.65 0.357 
Range 1.6 – 6.1 1.4 – 4.6  
Number of patients  ≥4.1 3 1  
HDL cholesterol (mmol/liter)  
Mean ± SD 1.40 ± 0.36 1.30 ± 0.36 0.331 
Range 0.8 – 2.1 0.7 – 1.9  
Number of patients  ≤1 4 5  
Triglyceride (mmol/liter)  
Mean ± SD 1.43 ± 0.86 1.24 ± 0.56 0.345 
Range 0.5 – 3.4 0.4 – 2.7  
Number of patients  ≥4.5 0 0  
 
* BMI denotes body mass index, MCV mean corpuscular volume, MCH mean 
corpuscular hemoglobin, MCHC mean corpuscular hemoglobin concentration, ALT 
alanine aminotransferase, AST aspartate aminotransferase, LDL low-density 
lipoprotein, HDL high-density lipoprotein and ULN upper limit of normal range. 
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 Number of patients (%)  
   
Any category 25 (100) 25 (100) 25 (100) 1.000 
   
Infection   
Total 20 (80) 22 (88) 42 (84) 0.702 
Upper respiratory infection, 
sinusitis, or bronchitis 
16 (64) 20 (80) 36 (72) 0.345 
Urinary tract infection or 
pyelonephritis 
4 (16) 2 (8) 6 (12) 0.667 
Pharyngitis 3 (12) 2 (8) 5 (10) 1.000 
Perioral 2 (8) 0 2 (4) 0.490 
Pain   
Total 18 (72) 19 (76) 37 (74) 1.000 
Flank pain 7 (28) 11 (44) 18 (36) 0.377 
Headache 12 (48) 3 (12) 15 (30) 0.012 
Muscoloskeletal 7 (28) 8 (32 15 (30) 1.000 
Abdominal  3 (12) 2 (8) 5 (10) 1.000 
Genital 2 (8) 1 (4) 3 (6) 1.000 
Gastrointestinal   
Total 21 (84) 8 (32) 29 (58) 0.0004 
Aphthous ulcer or mucositis 18 (72) 4 (16) 22 (44) 0.0001 
Diarrhea 9 (36) 5 (20) 14 (28) 0.345 
Teeth 2 (8) 0 2 (4) 0.490 
Heartburn 2 (8) 1 (4) 3 (6) 1.000 
Nausea 3 (12) 0 3 (6) 1.000 
Skin-related   
Total 13 (52) 10 (40) 23 (46) 0.571 
Acne 13 (52) 7 (28) 20 (40) 0.148 
Folliculitis 1 (4) 2 (8) 3 (6) 1.000 
Pulmonary or upper respiratory  
Cough 6 (24) 1 (4) 7 (14) 0.098 
Renal or genitourinary   
Macrohematuria 1 (4) 4 (16) 5 (10) 0.349 
Lymphatics   
Limb edema 3 (12) 0 3 (6) 0.235 
Neurologic   
Dizziness 3 (12) 0 3 (6) 0.235 
Blood and bone marrow   
Leucopenia 2 (8) 0 2 (4) 0.490 
Sexual or reproductive function  
Irregular menses 2 (8) 0 2 (4) 0.490 
 
* Table shows number of patients (percent). Adverse events affecting ≥5% in either 
group were described and graded according to the National Cancer Institute (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.  
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Figures 
Figure 1. Mean sirolimus dose (A), sirolimus dose per body weight (B) and sirolimus 




Figure 2. The amount of albumin (A) and transferrin (B) in 24-h urine collections at 6 
months. Lines represent median and interquartile range.  
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Figure 3. Mean corpuscular volume of erythrocytes (A) and red blood cell count (B) 
at month 6. The line represents the mean. Baseline mean values ± standard 
deviations are shown below the x-axis.  
 
 
Figure 4. Cholesterol (A) and triglyceride (B) levels were similar in both groups at 
baseline and at 6-month follow up. The box indicates 50% of the observed data 
points between the 1st and 3rd quartiles. The line within the box represents the 
median. The whiskers show the data between the 10th and 90th percentiles. 
 
 
